Teethgrinder – Lifestyle
Author:
Immunocore Holdings plc
KIMMTRAK doubles the likelihood of being alive at five years for first line HLA-A*02:01+ patients with metastatic uveal melanoma
April 19, 2026
Immunocore to present at the 25th Annual Needham Virtual Healthcare Conference
April 6, 2026
Immunocore will present five-year overall survival data for KIMMTRAK during oral presentation at the 2026 AACR meeting
March 17, 2026